Halozyme Therapeutics HALO Estimates

NASDAQ HALO
$109.94 -0.82 (-0.74%)
As of: Sep 4, 2026 · 11:48 AM EDT
Analyst Estimates

Halozyme Therapeutics, Inc. Revenue Estimates

Periods 27
Next Period Q2 26
Consensus 383.55 M

Analysts expect Halozyme Therapeutics, Inc. to report revenue of 383.55 M for Q2 26, against a range of 355.31 M to 411.79 M. The most recent reported quarter, Q1 26, came in at 376.71 M, a 12.1% beat against the 336.18 M consensus.

Metric Q2 24Q3 24Q4 24Q1 25Q2 25Q3 25Q4 25Q1 26Q2 26Q3 26Q4 26Q1 27Q2 27Q3 27Q4 27Q1 28Q2 28Q3 28Q4 28Q1 29Q2 29Q3 29Q4 29Q1 30Q2 30Q3 30Q4 30
Reported (Actual) 231.35 M290.08 M298.01 M264.86 M325.72 M354.26 M451.77 M376.71 M--------
High Estimate 199.92 M247.47 M280.50 M239.45 M322.36 M358.07 M454.98 M350.02 M411.79 M460.70 M509.09 M446.94 M538.80 M548.20 M668.32 M482.99 M
Low Estimate 184.23 M226.02 M251.46 M208.95 M282.29 M293.35 M379.14 M322.35 M355.31 M405.92 M477.97 M415.54 M492.95 M503.51 M564.71 M411.32 M
Consensus Estimate 192.07 M236.75 M265.98 M224.20 M302.33 M325.71 M417.06 M336.18 M383.55 M433.31 M493.53 M431.24 M515.87 M525.85 M616.52 M447.15 M
Analyst Estimates

Halozyme Therapeutics, Inc. Earnings Per Share (EPS) Estimates

Periods 27
Next Period Q2 26
Consensus 1.74

Analysts expect Halozyme Therapeutics, Inc. to report earnings per share of 1.74 for Q2 26, against a range of 1.67 to 1.81. The most recent reported quarter, Q1 26, came in at 1.60, a 7.4% beat against the 1.49 consensus.

Metric Q2 24Q3 24Q4 24Q1 25Q2 25Q3 25Q4 25Q1 26Q2 26Q3 26Q4 26Q1 27Q2 27Q3 27Q4 27Q1 28Q2 28Q3 28Q4 28Q1 29Q2 29Q3 29Q4 29Q1 30Q2 30Q3 30Q4 30
Reported (Actual) 0.911.271.261.111.541.72-0.241.60--------
High Estimate 0.861.141.280.991.371.642.461.561.812.392.732.372.423.002.992.62
Low Estimate 0.720.981.140.831.231.462.181.421.672.132.411.952.022.502.512.40
Consensus Estimate 0.791.061.210.911.301.552.321.491.742.262.572.162.222.752.752.51